DAVID SZAFRON to Humans
This is a "connection" page, showing publications DAVID SZAFRON has written about Humans.
Connection Strength
0.061
-
Duodenal and liver lesions in an adult with generalised weakness. Gut. 2020 09; 69(9):1-2.
Score: 0.018
-
Characteristics and Outcomes of Cancer Patients With Venous Thromboembolic Events After Treatment With Immune Checkpoint Inhibitors. Am J Clin Oncol. 2023 03 01; 46(3):94-100.
Score: 0.006
-
Endoscopy for the diagnosis and treatment of gastrointestinal bleeding caused by malignancy. J Gastroenterol Hepatol. 2022 Oct; 37(10):1983-1990.
Score: 0.006
-
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. Hepatol Commun. 2022 07; 6(7):1776-1785.
Score: 0.005
-
Ethnicity Is an Important Consideration in Screening for Gastric Intestinal Metaplasia. Dig Dis Sci. 2022 09; 67(9):4509-4517.
Score: 0.005
-
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice. Eur J Cancer. 2021 11; 157:140-152.
Score: 0.005
-
Endoscopic Ultrasound Finding of Diffuse Echogenicity in the Pancreas, Is It Relevant? Dig Dis Sci. 2022 07; 67(7):3244-3251.
Score: 0.005
-
Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy. J Immunother Cancer. 2020 10; 8(2).
Score: 0.005
-
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study. J Immunother Cancer. 2020 08; 8(2).
Score: 0.005